Association of Matrix Metalloproteinase-3 -1171(5A>6A) Polymorphism with Cancer Risk: a Meta-analysis of 41 Studies

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Feb 4

PMID 24489939

Citations 6

Authors

Xin Yang

Jing-Wen Hu

Man-Tang Qiu

Ming Li

Rong Yin

Jie Wang

Lin Xu

Qin Zhang

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Evidence has shown that matrix metalloproteinases-3 (MMP3) is important for cancer progression. Recent studies about the association between the -1171(5A>6A) polymorphism in MMP3 promoter region and cancer risk have yielded conflicting results.

Methodology/principal Findings: We performed a meta-analysis of 41 studies including 11112 cases and 11091 controls to determine whether the -1171(5A>6A) polymorphism of MMP3 was associated with cancer risk. We assessed the strength of association and performed sub-group analyses by cancer types, ethnicity, smoking status, genotyping method, source of controls and sample size. The pooled results revealed that no significant association of the -1171(5A>6A) polymorphism with overall cancer risk in any of four models. Further sub-group analysis revealed that individuals with the 6A allele had lower risk of gastrointestinal cancer in two models: heterozygote comparison (6A/5A vs. 5A/5A: OR=0.74, 95%CI: 0.60-0.91; I(2)=1.9%), and dominant model (6A/6A+6A/5A vs. 5A/5A: OR=0.77, 95%CI: 0.64-0.94; I(2)=29.0%). Additionally, the associations were significant in Asian populations for three models: homozygote comparison (6A/6A vs. 5A/5A, OR=0.68, 95%CI: 0.52-0.90; I(2)=26.7%), heterozygote comparison (6A/5A vs. 5A/5A: OR=0.75, 95%CI: 0.58-0.98; I(2)=0.0%), and dominant model (6A/6A+6A/5A vs. 5A/5A: OR=0.69, 95%CI: 0.54-0.88; I(2)=0.5%). It was noteworthy that we had a contrary finding in non-smokers: the variant 6A/6A homozygote might statistically increase cancer risk compared with 6A/5A+5A/5A genotype (OR=1.92, 95%CI: 1.25-2.96; I(2)=72.7%).

Conclusion: This meta-analysis suggests that the -1171(5A>6A) polymorphism in MMP3 promoter region is not associated with overall cancer risk, but it may contribute to decreased cancer risk in Asian population when compared with Caucasian population and significantly reduce the risk of gastrointestinal cancer.

Citing Articles

Matrilysins and Stromelysins in Pathogenesis and Diagnostics of Cancers.

Piskor B, Przylipiak A, Dabrowska E, Niczyporuk M, Lawicki S Cancer Manag Res. 2020; 12:10949-10964.

PMID: 33154674 PMC: 7608139. DOI: 10.2147/CMAR.S235776.

Association of matrix metalloproteinases 3 and 9 single nucleotide polymorphisms with breast cancer risk: A case-control study.

Abd Elmaogoud Ragab Ibrahim F, Essam Elfeky S, Haroun M, Abd Elrahman Ahmed M, Elnaggar M, Abd Elfatah Ismail N Mol Clin Oncol. 2020; 13(1):54-62.

PMID: 32454974 PMC: 7241239. DOI: 10.3892/mco.2020.2041.

Matrix Metallopeptidase 3 Polymorphisms: Emerging genetic Markers in Human Breast Cancer Metastasis.

Ahmad Suhaimi S, Chan S, Rosli R J Breast Cancer. 2020; 23(1):1-9.

PMID: 32140265 PMC: 7043940. DOI: 10.4048/jbc.2020.23.e17.

Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer.

Padala C, Tupurani M, Puranam K, Gantala S, Shyamala N, Kondapalli M PLoS One. 2017; 12(9):e0184448.

PMID: 28961241 PMC: 5621673. DOI: 10.1371/journal.pone.0184448.

Matrix Metalloproteinase-3 -1171 5A/6A Polymorphism (rs35068180) is Associated with Risk of Periodontitis.

Ding C, Chen X, Zhang P, Huang J, Xu Y, Chen N Sci Rep. 2015; 5:11667.

PMID: 26123623 PMC: 4485030. DOI: 10.1038/srep11667.

References

Wang J, Zou L, Song Z, Lang X, Huang S, Lu F . Meta-analysis of RAGE gene polymorphism and coronary heart disease risk. PLoS One. 2012; 7(12):e50790. PMC: 3516500. DOI: 10.1371/journal.pone.0050790. View

Kader A, Shao L, Dinney C, Schabath M, Wang Y, Liu J . Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006; 66(24):11644-8. DOI: 10.1158/0008-5472.CAN-06-1212. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Chambers A, Matrisian L . Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997; 89(17):1260-70. DOI: 10.1093/jnci/89.17.1260. View

Fathy M, Hamed M, Youssif O, Fawzy N, Ashour W . Association between environmental tobacco smoke exposure and lung cancer susceptibility: modification by antioxidant enzyme genetic polymorphisms. Mol Diagn Ther. 2013; 18(1):55-62. DOI: 10.1007/s40291-013-0051-6. View

Somerville R, Oblander S, Apte S . Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 2003; 4(6):216. PMC: 193609. DOI: 10.1186/gb-2003-4-6-216. View

Woo M, Park K, Nam J, Kim J . Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2007; 22(7):1064-70. DOI: 10.1111/j.1440-1746.2006.04424.x. View

Johnsen M, Lund L, Romer J, Almholt K, Dano K . Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 1998; 10(5):667-71. DOI: 10.1016/s0955-0674(98)80044-6. View

Curran S, Murray G . Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000; 36(13 Spec No):1621-30. DOI: 10.1016/s0959-8049(00)00156-8. View

10.

Li Y, Jin X, Kang S, Wang Y, Du H, Zhang J . Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol. 2005; 101(1):92-6. DOI: 10.1016/j.ygyno.2005.09.058. View

11.

Qiu M, Hu J, Ding X, Yang X, Zhang Z, Yin R . Hsa-miR-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PLoS One. 2012; 7(12):e50887. PMC: 3517592. DOI: 10.1371/journal.pone.0050887. View

12.

Lau J, Ioannidis J, Schmid C . Quantitative synthesis in systematic reviews. Ann Intern Med. 1998; 127(9):820-6. DOI: 10.7326/0003-4819-127-9-199711010-00008. View

13.

Yin L, Morita A, Tsuji T . Alterations of extracellular matrix induced by tobacco smoke extract. Arch Dermatol Res. 2000; 292(4):188-94. DOI: 10.1007/s004030050476. View

14.

Boudreau N, Sympson C, Werb Z, Bissell M . Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science. 1995; 267(5199):891-3. PMC: 3004777. DOI: 10.1126/science.7531366. View

15.

Smolarz B, Szyllo K, Romanowicz-Makowska H, Niewiadomski M, Kozlowska E, Kulig A . PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol. 2004; 54(4):233-8. View

16.

Lu Z, Wang Y, Cao Y, Zhang Q, Zhang X, Li Y . [Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma]. Ai Zheng. 2007; 26(5):463-8. View

17.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

18.

Sternlicht M, Bissell M, Werb Z . The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene. 2000; 19(8):1102-13. PMC: 2933206. DOI: 10.1038/sj.onc.1203347. View

19.

Nishizawa R, Nagata M, Noman A, Kitamura N, Fujita H, Hoshina H . The 2G allele of promoter region of matrix metalloproteinase-1 as an essential pre-condition for the early onset of oral squamous cell carcinoma. BMC Cancer. 2007; 7:187. PMC: 2089080. DOI: 10.1186/1471-2407-7-187. View

20.

Motovali-Bashi M, Hojati Z, Hajihoseiny S, Hemmati S . The stromelysin-1 5A/5A genotype enhances colorectal cancer cell invasion in Iranian population. J Res Med Sci. 2013; 17(10):962-6. PMC: 3698657. View